Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

      TERMINATED
      Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
      Description

      This phase II trial studies how well capmatinib, ceritinib, regorafenib, or entrectinib work in treating patients with BRAF/NRAS wild-type stage III-IV melanoma. Capmatinib, ceritinib, regorafenib, or entrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

      Conditions
      ALK Fusion Protein ExpressionBRAF wt AlleleInvasive Skin MelanomaMET Fusion Gene PositiveNRAS wt AlleleNTRK1 Fusion PositiveNTRK2 Fusion PositiveNTRK3 Fusion PositiveRET Fusion PositiveROS1 Fusion PositiveStage III Cutaneous MelanomaStage IIIA Cutaneous MelanomaStage IIIB Cutaneous MelanomaStage IIIC Cutaneous MelanomaStage IV Cutaneous Melanoma
      Talk to us
      RECRUITING
      APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
      Description

      To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET * efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistance with MET amplification and disease progression after documented CR or PR with 1st line EGFR inhibitors (EGFR-I)

      Conditions
      Solid TumorsAdvanced CancerRenal CancerGastric CancerGastroesophageal Junction AdenocarcinomaNSCLCLung CancerBrain TumorGlioblastoma MultiformeEGFR Gene MutationMET AmplificationHGFThyroid CancerPancreatic CancerColon CancerMET AlterationMET FusionExon 14 Skipping
      Talk to us